Centro / Instituto vinculado a la Universidad de Navarra
Centro de Investigación de Medicina Aplicada (CIMA)
Publicaciones (90) Publicaciones en las que ha participado algún/a investigador/a
2024
-
A Focus on the Pathophysiology of Adrenomedullin Expression: Endothelitis and Organ Damage in Severe Viral and Bacterial Infections
Cells, Vol. 13, Núm. 11
-
AI is a viable alternative to high throughput screening: a 318-target study
Scientific Reports, Vol. 14, Núm. 1
-
Agrypnia Excitata and Supranuclear Vertical Gaze Palsy Linked to Anti-Ma Encephalitis
Movement Disorders Clinical Practice, Vol. 11, Núm. 5, pp. 571-574
-
An atlas of cells in the human tonsil
Immunity, Vol. 57, Núm. 2, pp. 379-399.e18
-
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/ MINOVA Study)
Clinical Cancer Research, Vol. 30, Núm. 1, pp. 176-186
-
Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1
JHEP Reports, Vol. 6, Núm. 1
-
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096
-
Biomaterials-Based Antioxidant Strategies for the Treatment of Oxidative Stress Diseases
Biomimetics, Vol. 9, Núm. 1
-
CALR but Not JAK2 Mutations Are Associated with an Overexpression of Retinoid X Receptor Alpha in Essential Thrombocythemia
Cancers, Vol. 16, Núm. 8
-
CD3 aptamers promote expansion and persistence of tumor-reactive T cells for adoptive T cell therapy in cancer
Molecular Therapy Nucleic Acids, Vol. 35, Núm. 2
-
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Nature Communications, Vol. 15, Núm. 1
-
Characterization of immune populations in the tumor microenvironment of diffuse midline glioma orthotopic mouse models by flow cytometry
STAR Protocols, Vol. 5, Núm. 1
-
Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice
Molecular Therapy, Vol. 32, Núm. 3, pp. 722-733
-
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Clinical Cancer Research, Vol. 30, Núm. 7, pp. 1319-1326
-
Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming
Immunological Reviews, Vol. 321, Núm. 1, pp. 143-151
-
Deciphering the Role of Post-Translational Modifications and Cellular Location of Hepatitis Delta Virus (HDV) Antigens in HDV-Mediated Liver Damage in Mice
Viruses, Vol. 16, Núm. 3
-
Dendritic Cells in Cancer Immunology and Immunotherapy
Cancers, Vol. 16, Núm. 5
-
Development and characterization of a non-human primate model of disseminated synucleinopathy
Frontiers in Neuroanatomy, Vol. 18
-
Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4
-
Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1
EMBO molecular medicine, Vol. 16, Núm. 1, pp. 112-131